8A
8AP.F Agios Pharmaceuticals Inc
- Market cap
- EUR 1.70B
- P/E
- -
- P/B
- 1.86x
- ROE
- -36.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8AP.F undervalued?
Graham numberThe Graham number of Agios Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Agios Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Agios Pharmaceuticals Inc yet.
Agios Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of …
Full company profileAgios Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Agios Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 69.9M | 43.0M | 94.4M | 118M | 203M | 203M | 14.2M | 26.8M | 36.5M | 54.0M | 161M |
| Gross Profit | -150M | -250M | 93.0M | 117M | 200M | 0.00 | 12.5M | 23.9M | 32.3M | 47.7M | 152M |
| Operating Income | -201M | -321M | -362M | -426M | -316M | -378M | -389M | -391M | -426M | -472M | -397M |
| EBITDA | - | -314M | -355M | -418M | -300M | -369M | -380M | -385M | -420M | -467M | -391M |
| Net Income | -198M | -315M | -346M | -411M | -327M | 1.60B | -232M | -352M | 674M | -413M | -353M |
| EPS | - | -6.44 | -5.94 | -6.02 | -4.72 | 30 | -4.21 | -6.29 | 12 | -7.06 | -5.91 |
| Balance Sheet | |||||||||||
| Total Assets | 619M | 614M | 858M | 891M | 853M | 1.44B | 1.24B | 937M | 1.66B | 1.30B | 1.06B |
| Total Liabilities | 261M | 239M | 171M | 250M | 453M | 146M | 138M | 126M | 122M | 104M | 84.7M |
| Shareholders' Equity | 359M | 376M | 688M | 641M | 400M | 1.29B | 1.10B | 811M | 1.54B | 1.19B | 979M |
| Cash & Short-term Investments | 161M | 103M | 70.5M | 80.9M | 127M | 203M | 139M | 88.2M | 76.2M | 89.1M | 129M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 38.6M | -285M | -304M | -371M | -291M | -407M | -309M | -296M | -390M | -373M | -314M |
| Capital Expenditure | 9.92M | 4.63M | 6.99M | 12.0M | 14.1M | 5.74M | 4.88M | 18.5M | 1.69M | 14.3M | 37.6M |
| Free Cash Flow | - | -290M | -311M | -383M | -306M | -413M | -314M | -315M | -392M | -387M | -352M |
| Ratios | |||||||||||
| ROE | -55.3% | -83.8% | -50.3% | -64.2% | -81.9% | 124.2% | -21.1% | -43.4% | 43.7% | -34.6% | -36.1% |
| ROA | -32.1% | -51.2% | -40.3% | -46.2% | -38.4% | 111.6% | -18.7% | -37.6% | 40.5% | -31.8% | -33.2% |
| Net Profit Margin | -284.0% | -731.6% | -366.6% | -349.0% | -161.1% | 789.7% | -1,627.8% | -1,312.6% | 1,845.9% | -764.0% | -219.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Agios Pharmaceuticals Inc dividends
Agios Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Agios Pharmaceuticals Inc
- Insiders 1.07%
- Institutions 98.93%
- Public & others 0.00%
- Shares outstanding 59.8M
- Free float 50.1M
Agios Pharmaceuticals Inc company profile
- Company name
- Agios Pharmaceuticals Inc
- Ticker
- 8AP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 539
- Fiscal year end
- December
- Address
- 88 Sidney Street, Cambridge, MA, United States, 02139
- Phone
- 617 649 8600
- Website
- agios.com
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals Inc management
10- Mr. Brian M. Goff M.B.A.CEO & Director · born 1969
- Ms. Cecilia JonesChief Financial Officer · born 1975
- Dr. Krishnan Viswanadhan M.B.A., Pharm.D.Chief Strategy & Operations Officer · born 1979
- Mr. James William BurnsChief Legal Officer · born 1978
- Dr. Sarah Gheuens M.D., Ph.D.Chief Medical Officer and Head of Research & Development · born 1980
- Dr. Lewis clayton Cantley Ph.D.Co-Founder · born 1949
- Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.Co-Founder · born 1946
- Dr. Craig B. Thompson M.D.Co-Founder · born 1953
- Dr. Shin-San Su Ph.D.Co-Founder · born 1956
- Mr. T. J. WashburnVP, Controller & Principal Accounting Officer · born 1982